The catalyst: When the FDA grants a Regenerative Medicine Advanced Therapy (RMAT) designation, it isn't just a headline for the sponsor — it's a signal that a delivery mechanism works well enough to fast-track. Intellia (NTLA) now holds RMAT status for nexiguran ziclumeran across both ATTR amyloidosis presentations (cardiomyopathy and polyneuropathy), on top of a resumed Phase 3 after the FDA lifted its clinical hold in March 2026. Each of those signals validates the same underlying plumbing: lipid-nanoparticle (LNP) delivery that ferries CRISPR machinery to the liver and gets cleared from the body. That plumbing is licensed, not homegrown — which means regulatory validation of Intellia's editor cascades value to whoever owns the delivery IP, the manufacturing know-how, and the collaboration economics sitting behind NTLA's name on the label.
Who cashes in: